Bright Minds Biosciences (DRUG) vs Oculis (OCS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Bright Minds Biosciences (DRUG) has outperformed Oculis (OCS) over the past year, losing 12.0% versus a loss of 60.5%. Over five years, DRUG leads with a +45.5% price change compared with -15.1% for OCS. Bright Minds Biosciences is the larger company by market cap ($533.2 million vs $513.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DRUG | OCS |
|---|---|---|
| Share price | $54.05 | $8.34 |
| Market cap | $533.15M | $513.64M |
| 1-day change | +3.94% | -3.70% |
| YTD return | -30.74% | -58.24% |
| 1-year return | -11.99% | -60.53% |
| 5-year return | +45.49% | -15.07% |
| EPS (TTM) | $-2.13 | $-1.68 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $123.75 | $34.48 |
| 52-week low | $47.23 | $8.30 |
| Distance from 52-week high | -56.32% | -75.81% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +181.17% | +340.29% |
| Average volume | 156.28K | 257.88K |
| Shares outstanding | 9.86M | 61.59M |
| Employees | 26 | 60 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DRUG has outperformed OCS by 48.5 percentage points over the past year.
- The two companies sit in different sectors: Bright Minds Biosciences in Health Care and Oculis in Healthcare.
About Bright Minds Biosciences
DRUG stock →Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.
Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees
About Oculis
OCS stock →Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Healthcare · Biotechnology · 60 employees
DRUG vs OCS FAQ
Which is bigger, Bright Minds Biosciences or Oculis?
Bright Minds Biosciences (DRUG) is larger, with a market capitalization of $533.15M compared with $513.64M for Oculis (OCS).
Which stock has performed better over the past year, DRUG or OCS?
DRUG returned -11.99% over the past 12 months, compared with -60.53% for OCS (price return, excluding dividends). Past performance does not predict future results.
Are Bright Minds Biosciences and Oculis in the same industry?
No. Bright Minds Biosciences is in the Health Care sector, while Oculis is in Healthcare.